Form 8-K - Current report:
SEC Accession No. 0001437749-25-006757
Filing Date
2025-03-10
Accepted
2025-03-10 08:02:05
Documents
15
Period of Report
2025-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K urgn20250304_8k.htm   iXBRL 8-K 31133
2 PRESS RELEASE DATED MARCH 10, 2025 ex_785682.htm EX-99.1 80669
  Complete submission text file 0001437749-25-006757.txt   263145

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA urgn-20250310.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE urgn-20250310_def.xml EX-101.DEF 11806
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20250310_lab.xml EX-101.LAB 15857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20250310_pre.xml EX-101.PRE 12021
17 EXTRACTED XBRL INSTANCE DOCUMENT urgn20250304_8k_htm.xml XML 2971
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 25722201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)